DETECTION OF SARS-CoV-2 ANTIBODIES
PerkinElmer Assays for Detection of SARS-CoV-2 Antibodies
Immunoassays detect antibodies to SARS-CoV-2 instead of identifying the live virus. According to the FDA, antibodies to SARS-CoV-2 develop approximately one to three weeks after infection and persist for a long period of time. Therefore, antibody determination is not a suitable measure to identify people who are infectious. They are not suitable to determine the difference between a sample from a person with an active infection who can spread the disease and a sample from a person who has recovered from the infection. However, they can be quite valuable as a tool for disease surveillance and investigational purposes.
PerkinElmer offers a number of different types of SARS-CoV-2 immunoassays with varied samples types, throughputs, run times, and targets. The table below will help you decide which solution best fits your needs.
|
Direct chemiluminescence |
Immuno-chromatography |
GSP®/DELFIA®
Time-resolved fluorescence |
EUROIMMUN*
Enzyme-linked immunosorbent assay |
|
|---|---|---|---|---|
| Run Time | 15 minutes (12 samples) |
20 minutes (1 sample) |
< 2 hours (96 samples) |
2.5 hours |
| Throughput (24 hours) |
Automated ~ 1,152 | Manual – Variable | Automated ~ 5,000 | Automated ~ 2,100 Manual – Variable |
| Ab target | IgG (S1) | IgA+IgM+IgG (S1) | IgG (S1) | IgA (S1) IgM (NCP) IgG (S1, NCP) |
| Sample type | Serum, Plasma, Whole Blood | Serum, Plasma, Fingerpick Whole Blood | Serum, Dried Blood Spot | Serum, Dried Blood Spot for IgG |
Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please check with your local representative for availability.
* For emergency use authorization only. Products may not be licensed in accordance with the laws in all countries. Please check with your local representative for availability.